Primitive neuroectodermal tumor of the cervix uteri

Primitive neuroectodermal tumor (PNET) of the cervix uteri is an extremely rare malignant neoplasm arising in the uterine cervix. It belongs to the family of small round blue cell tumors that are thought to originate from neuroectodermal progenitor cells. Also referred to as peripheral PNET or Ewing sarcoma family tumor of the cervix, this neoplasm is characterized by sheets of small, round, undifferentiated cells that may express neural markers such as CD99, synaptophysin, and neuron-specific enolase. Molecular analysis may reveal the characteristic EWSR1-FLI1 translocation t(11;22)(q24;q12) seen in the Ewing sarcoma family of tumors. Clinically, patients typically present with abnormal vaginal bleeding, pelvic pain, or a cervical mass detected on gynecological examination. The tumor tends to be aggressive, with a propensity for local invasion and distant metastasis to sites including the lungs, liver, and bone. Diagnosis requires histopathological examination with immunohistochemistry and often molecular or cytogenetic confirmation to distinguish it from other small round cell tumors of the cervix, such as small cell carcinoma or rhabdomyosarcoma. Due to its extreme rarity, there are no standardized treatment guidelines. Management is generally extrapolated from protocols used for Ewing sarcoma and other PNETs at other anatomical sites, typically involving a multimodal approach combining radical surgery (such as radical hysterectomy), chemotherapy (often Ewing sarcoma-type regimens including vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide), and radiation therapy. Prognosis is generally poor, particularly in advanced-stage disease, though early-stage tumors treated aggressively may have better outcomes. Fewer than 50 cases have been reported in the medical literature, making evidence-based recommendations challenging.

Common questions about Primitive neuroectodermal tumor of the cervix uteri